This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Tenapanor for Irritable Bowel Syndrome with Constipation

Irritable bowel syndrome with constipation (IBS-C) is a common condition that affects the digestive system (the gut). Symptoms may include stomach cramps, bloating and constipation. The exact cause is unknown, and IBS-C is often a lifelong condition. While there is no cure, dietary changes and the use of medication can often help control symptoms. IBS-C has been linked to issues of digestion, stress, and a family history of the condition. IBS-C affects approximately 7-21% of the population globally and is a significant health care burden impacting health and quality of life of affected individuals. Treatment of IBS-C is particularly challenging as symptoms fluctuate over time and are often recurrent and resistant to administered drugs.
Tenapanor is an oral drug under development for the treatment of IBS-C. It acts directly in the gut to reduce absorption of sodium. Sodium increases fluid in the gut, loosening stool, and alleviating constipation. If licensed, tenapanor may offer an additional treatment option for IBS-C by increasing intestinal fluid content, accelerating gastrointestinal (GI) motility, and providing relief from symptomatic pain and discomfort. By acting directly in the gut, tenapanor also has a potential advantage of having minimal side effects.

Download Full Article

Twitter

Related Posts

Ustekinumab is a drug which is given as an injection and works by blocking the molecules that are involved in the inflammation which occurs in UC. Ustekinumab is already licenced for use in people with Crohn’s disease, which is another type of IBD. If ustekinumab is licenced this would provide another treatment option for people with moderate to severe active UC.

Selonsertib is an investigational oral small molecule inhibitor of ASK1, a protein that mediates inflammation, apoptosis (cell death) and fibrosis in settings of oxidative stress. Oxidative stress can be increased in many pathological conditions including liver diseases such as NASH. NASH currently has no effective treatment apart from lifestyle interventions. If licensed, selonsertib will offer a new treatment option for NASH as no effective pharmacological therapies currently exist.

Timolumab is currently being developed to treat PSC. Timolumab is given by injection into the vein which blocks a molecule called VAP-1 from working. VAP-1 helps immune cells enter areas of inflammation (such as the bile ducts in PSC) where they can further contribute to inflammation. By blocking this process, timolumab has the potential to prevent some of the inflammation in PSC and slow the progress of the disease.

Currently, there are no approved therapies for the treatment of NASH, but doctors recommend dietary changes and exercise to prevent or slow disease progression. Volixibat is a new experimental once-daily oral tablet that may improve NASH by targeting and blocking a protein (apical sodium-dependent bile acid transporter) found in the liver. This is thought to …